Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 – For Medical Students & Physicians A complete 20-lesson, 300-page Chinese HSK 1 course with a companion app in 21 languages — free forever. Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Obesity

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 94 articles: HTML format

Single Articles

April 2026
1. ROSEN CJ, Ingelfinger JR
   GLP-1 Receptor Agonists.
   N Engl J Med. 2026;394:1313-1324.
   PubMed     Abstract available
   
   
   December 2025
2. WHARTON S, Duque do Vale R, Garvey WT
   Oral Semaglutide in Adults with Overweight or Obesity. Reply.
   N Engl J Med. 2025;393:2383.
   PubMed    
   
   
   
3. LIU H, Sun F, Wu J
   Oral Semaglutide in Adults with Overweight or Obesity.
   N Engl J Med. 2025;393:2382.
   PubMed    
   
   
   
4. KERMANSARAVI M, Cohen RV
   Oral Semaglutide in Adults with Overweight or Obesity.
   N Engl J Med. 2025;393:2381-2382.
   PubMed    
   
   
   
5. JASTREBOFF AM, Ryan DH, Pannacciulli N
   Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial. Reply.
   N Engl J Med. 2025;393:2275.
   PubMed    
   
   
   
6. MUSKIET MHA, Smits MM
   Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial.
   N Engl J Med. 2025;393:2274-2275.
   PubMed    
   
   
   
7. LIU QK
   Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial.
   N Engl J Med. 2025;393:2274.
   PubMed    
   
   
   November 2025
8. DAVIES MJ, Broholm C, Garvey WT
   Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.
   N Engl J Med. 2025;393:2067-2068.
   PubMed    
   
   
   
9. GARVEY WT, Osorto Contreras CK, Davies MJ
   Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.
   N Engl J Med. 2025;393:2067.
   PubMed    
   
   
   
10. CHI H, Yang H, Deng Y
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2025;393:2067.
    PubMed    
    
    
    
11. LNU V, Noor F
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2025;393:2066-2067.
    PubMed    
    
    
    
12. KRAKAUER JC, Krakauer NY
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2025;393:2066.
    PubMed    
    
    
    
13. FOGACCI F, Cicero AFG
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2025;393:2065-2066.
    PubMed    
    
    
    October 2025
14. ARONNE LJ
    Tirzepatide vs. Semaglutide for Obesity Treatment. Reply.
    N Engl J Med. 2025;393:1655-1656.
    PubMed    
    
    
    
15. ABDULLAYEV N, Sanduleanu S
    Tirzepatide vs. Semaglutide for Obesity Treatment.
    N Engl J Med. 2025;393:1655.
    PubMed    
    
    
    
16. MUSKIET MHA, Winter EM, Rensen PCN
    Tirzepatide vs. Semaglutide for Obesity Treatment.
    N Engl J Med. 2025;393:1654-1655.
    PubMed    
    
    
    September 2025
17. WHARTON S, Lingvay I, Bogdanski P, Duque do Vale R, et al
    Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.
    N Engl J Med. 2025;393:1077-1087.
    PubMed     Abstract available
    
    
    
18. WHARTON S, Aronne LJ, Stefanski A, Alfaris NF, et al
    Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
    N Engl J Med. 2025 Sep 16. doi: 10.1056/NEJMoa2511774.
    PubMed     Abstract available
    
    
    
19. JI L, Qian L
    Once-Weekly Mazdutide in Obesity or Overweight. Reply.
    N Engl J Med. 2025;393:10.
    PubMed    
    
    
    
20. ZHANG Y, Yu L, Liu ZT
    Once-Weekly Mazdutide in Obesity or Overweight.
    N Engl J Med. 2025;393:10.
    PubMed    
    
    
    August 2025
21. KOTANIDIS CP, Lincoff AM, Shikora SA
    Managing Obesity.
    N Engl J Med. 2025;393:719-721.
    PubMed    
    
    
    
22. HALES CM
    Expanding the Treat-to-Target Toolbox for Obesity and Diabetes Care.
    N Engl J Med. 2025;393:712-714.
    PubMed    
    
    
    July 2025
23. GREENWAY FL
    Semaglutide and Tirzepatide to Treat Obesity.
    N Engl J Med. 2025;393:84-85.
    PubMed    
    
    
    June 2025
24. JASTREBOFF AM, Bunck MC, Ahmad NN
    Tirzepatide for Obesity Treatment and Diabetes Prevention. Reply.
    N Engl J Med. 2025;392:2492-2493.
    PubMed    
    
    
    
25. SHUKLA AK, Bhavya B
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2025;392:2492.
    PubMed    
    
    
    
26. BIRKENFELD AL, Bergman M, Stefan N
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2025;392:2491-2492.
    PubMed    
    
    
    
27. JASTREBOFF AM, Ryan DH, Bays HE, Ebeling PR, et al
    Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.
    N Engl J Med. 2025 Jun 23. doi: 10.1056/NEJMoa2504214.
    PubMed     Abstract available
    
    
    
28. GARVEY WT, Bluher M, Osorto Contreras CK, Davies MJ, et al
    Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2025 Jun 22. doi: 10.1056/NEJMoa2502081.
    PubMed     Abstract available
    
    
    
29. DAVIES MJ, Bajaj HS, Broholm C, Eliasen A, et al
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
    N Engl J Med. 2025 Jun 22. doi: 10.1056/NEJMoa2502082.
    PubMed     Abstract available
    
    
    May 2025
30. JI L, Jiang H, Bi Y, Li H, et al
    Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
    N Engl J Med. 2025 May 25. doi: 10.1056/NEJMoa2411528.
    PubMed     Abstract available
    
    
    
31. ARODA VR, Perreault L
    Overweight and Obesity - Capturing the Whole Picture.
    N Engl J Med. 2025 May 25. doi: 10.1056/NEJMe2505819.
    PubMed    
    
    
    
32. ARONNE LJ, Horn DB, le Roux CW, Ho W, et al
    Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
    N Engl J Med. 2025 May 11. doi: 10.1056/NEJMoa2416394.
    PubMed     Abstract available
    
    
    
33. FOX CK, Harder-Lauridsen NM, Arslanian S
    Liraglutide for Children 6 to <12 Years of Age with Obesity. Reply.
    N Engl J Med. 2025;392:1868.
    PubMed    
    
    
    
34. EGAN JM, Kapogiannis D
    Liraglutide for Children 6 to <12 Years of Age with Obesity.
    N Engl J Med. 2025;392:1866-1868.
    PubMed    
    
    
    
35. JI C, Wang M
    Liraglutide for Children 6 to <12 Years of Age with Obesity.
    N Engl J Med. 2025;392:1867.
    PubMed    
    
    
    
36. MALOZOWSKI S
    Liraglutide for Children 6 to <12 Years of Age with Obesity.
    N Engl J Med. 2025;392:1866-1867.
    PubMed    
    
    
    April 2025
37. PACKER M, Kramer CM, Borlaug BA
    Tirzepatide for Heart Failure and Obesity. Reply.
    N Engl J Med. 2025;392:1661-1662.
    PubMed    
    
    
    
38. ALI MK
    Tirzepatide for Heart Failure and Obesity.
    N Engl J Med. 2025;392:1661.
    PubMed    
    
    
    
39. MARINE JE, Mandrola J, Prasad V
    Tirzepatide for Heart Failure and Obesity.
    N Engl J Med. 2025;392:1660.
    PubMed    
    
    
    
40. KRAKAUER JC, Krakauer NY
    Tirzepatide for Heart Failure and Obesity.
    N Engl J Med. 2025;392:1660.
    PubMed    
    
    
    
41. WAGNER J
    Tirzepatide for Heart Failure and Obesity.
    N Engl J Med. 2025;392:1659-1660.
    PubMed    
    
    
    March 2025
42. MAGNUSSEN C, Alegre-Diaz J, Al-Nasser LA, Amouyel P, et al
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025 Mar 30. doi: 10.1056/NEJMoa2415879.
    PubMed     Abstract available
    
    
    November 2024
43. PACKER M, Zile MR, Kramer CM, Baum SJ, et al
    Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2410027.
    PubMed     Abstract available
    
    
    
44. RUBIN EJ, Leopold J, Morrissey S
    NEJM at AHA - Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMe2414470.
    PubMed    
    
    
    
45. JASTREBOFF AM, le Roux CW, Stefanski A, Aronne LJ, et al
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819.
    PubMed     Abstract available
    
    
    October 2024
46. BLIDDAL H, Bays H, Czernichow S, Udden Hemmingsson J, et al
    Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.
    N Engl J Med. 2024;391:1573-1583.
    PubMed     Abstract available
    
    
    
47. 
    Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
    N Engl J Med. 2024;391:1464.
    PubMed    
    
    
    September 2024
48. DRUCKER DJ
    Discovery of GLP-1-Based Drugs for the Treatment of Obesity.
    N Engl J Med. 2024 Sep 19. doi: 10.1056/NEJMcibr2409089.
    PubMed    
    
    
    
49. BARRETT T, Hamilton-Shield J
    Childhood Obesity and GLP-1 Receptor Agonists - A Coming of Age?
    N Engl J Med. 2024 Sep 10. doi: 10.1056/NEJMe2410560.
    PubMed    
    
    
    
50. FOX CK, Barrientos-Perez M, Bomberg EM, Dcruz J, et al
    Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.
    N Engl J Med. 2024 Sep 10. doi: 10.1056/NEJMoa2407379.
    PubMed     Abstract available
    
    
    July 2024
51. KOSIBOROD MN, Petrie MC, Borlaug BA
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes. Reply.
    N Engl J Med. 2024;391:381-382.
    PubMed    
    
    
    
52. AMMON JP, Jackson CD
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:381.
    PubMed    
    
    
    
53. WAGNER J
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:380-381.
    PubMed    
    
    
    
54. COHEN C, Cohen R, Sabouret P
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:380.
    PubMed    
    
    
    June 2024
55. MALHOTRA A, Grunstein RR, Fietze I, Weaver TE, et al
    Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
    N Engl J Med. 2024 Jun 21. doi: 10.1056/NEJMoa2404881.
    PubMed     Abstract available
    
    
    
56. 
    Treating Obesity in Kids: ITT Episode 31.
    N Engl J Med. 2024;390:e52.
    PubMed    
    
    
    May 2024
57. EMANUEL EJ, Dellgren JL, McCoy MS, Persad G, et al
    Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.
    N Engl J Med. 2024;390:1839-1842.
    PubMed    
    
    
    
58. EGAN JM
    Physiological Integration of Taste and Metabolism.
    N Engl J Med. 2024;390:1699-1710.
    PubMed    
    
    
    April 2024
59. KOSIBOROD MN, Petrie MC, Borlaug BA, Butler J, et al
    Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2313917.
    PubMed     Abstract available
    
    
    February 2024
60. LINCOFF AM, Ryan DH, Esbjerg S
    Semaglutide and Cardiovascular Outcomes. Reply.
    N Engl J Med. 2024;390:768-769.
    PubMed    
    
    
    
61. NEVES JS, Leite AR, Ferreira JP
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767-768.
    PubMed    
    
    
    
62. CAMPBELL LA, Jenkins AV, Jackson CD
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    PubMed    
    
    
    
63. BELKHOURIBCHIA J
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    PubMed    
    
    
    
64. BELALCAZAR LM, Kuo YF
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766-767.
    PubMed    
    
    
    
65. TAQUETI VR, Shaw LJ
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766.
    PubMed    
    
    
    
66. GORTMAKER SL, Bleich SN, Williams DR
    Childhood Obesity Prevention - Focusing on Population-Level Interventions and Equity.
    N Engl J Med. 2024;390:681-683.
    PubMed    
    
    
    
67. GOLOVATY I, Hagan S
    Direct-to-Consumer Platforms for New Antiobesity Medications - Concerns and Potential Opportunities.
    N Engl J Med. 2024;390:677-680.
    PubMed    
    
    
    December 2023
68. KOSIBOROD MN, Borlaug BA, Petrie MC
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity. Reply.
    N Engl J Med. 2023;389:2398-2399.
    PubMed    
    
    
    
69. O'DOWLING R
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2398.
    PubMed    
    
    
    
70. WAGNER J
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2398.
    PubMed    
    
    
    
71. GAO Y, Gao Y, Qiu H
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2397-2398.
    PubMed    
    
    
    
72. WHARTON S, Konig M
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply.
    N Engl J Med. 2023;389:2304-2305.
    PubMed    
    
    
    
73. POURKARIM F, Entezari-Maleki T
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023;389:2303-2304.
    PubMed    
    
    
    
74. PRESTON W
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023;389:2303.
    PubMed    
    
    
    November 2023
75. LINCOFF AM, Brown-Frandsen K, Colhoun HM, Deanfield J, et al
    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2307563.
    PubMed     Abstract available
    
    
    
76. KHERA A, Powell-Wiley TM
    SELECTing Treatments for Cardiovascular Disease - Obesity in the Spotlight.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMe2312646.
    PubMed    
    
    
    October 2023
77. JASTREBOFF AM, Kaplan LM, Hartman ML
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.
    N Engl J Med. 2023;389:1629-1630.
    PubMed    
    
    
    
78. ELFEKI MA, Alkhouri N
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
    N Engl J Med. 2023;389:1629.
    PubMed    
    
    
    
79. BISSON A, Fauchier G, Fauchier L
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
    N Engl J Med. 2023;389:1628.
    PubMed    
    
    
    
80. HANNON TS, Arslanian SA
    Obesity in Adolescents. Reply.
    N Engl J Med. 2023;389:1344.
    PubMed    
    
    
    
81. BHOWMIK S, Mahapatra HS
    Obesity in Adolescents.
    N Engl J Med. 2023;389:1343-1344.
    PubMed    
    
    
    
82. ABU DAYYEH B, Stier C
    Obesity in Adolescents.
    N Engl J Med. 2023;389:1343.
    PubMed    
    
    
    August 2023
83. 
    Obesity and Heart Failure.
    N Engl J Med. 2023;389:e15.
    PubMed    
    
    
    
84. KOSIBOROD MN, Abildstrom SZ, Borlaug BA, Butler J, et al
    Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023 Aug 25. doi: 10.1056/NEJMoa2306963.
    PubMed     Abstract available
    
    
    
85. PATTI ME
    Triple G Agonists - A Home Run for Obesity?
    N Engl J Med. 2023;389:562-563.
    PubMed    
    
    
    July 2023
86. HANNON TS, Arslanian SA
    Obesity in Adolescents.
    N Engl J Med. 2023;389:251-261.
    PubMed    
    
    
    June 2023
87. JASTREBOFF AM, Kaplan LM, Frias JP, Wu Q, et al
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
    N Engl J Med. 2023 Jun 26. doi: 10.1056/NEJMoa2301972.
    PubMed     Abstract available
    
    
    
88. WHARTON S, Blevins T, Connery L, Rosenstock J, et al
    Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023 Jun 23. doi: 10.1056/NEJMoa2302392.
    PubMed     Abstract available
    
    
    
89. STOOPS H, Dar M
    Equity and Obesity Treatment - Expanding Medicaid-Covered Interventions.
    N Engl J Med. 2023;388:2309-2311.
    PubMed    
    
    
    
90. ROSEN CJ
    Antagonizing the Leptin Receptor in Obesity.
    N Engl J Med. 2023;388:2291-2293.
    PubMed    
    
    
    
91. FUNCKE JB, Moepps B, Roos J, von Schnurbein J, et al
    Rare Antagonistic Leptin Variants and Severe, Early-Onset Obesity.
    N Engl J Med. 2023;388:2253-2261.
    PubMed     Abstract available
    
    
    March 2023
92. WEGHUBER D, Kelly AS, Arslanian S
    Once-Weekly Semaglutide in Adolescents with Obesity. Reply.
    N Engl J Med. 2023;388:1146.
    PubMed    
    
    
    
93. MALOZOWSKI S
    Once-Weekly Semaglutide in Adolescents with Obesity.
    N Engl J Med. 2023;388:1145-1146.
    PubMed    
    
    
    
94. SNAITH JR, Greenfield JR
    Once-Weekly Semaglutide in Adolescents with Obesity.
    N Engl J Med. 2023;388:1145.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Obesity is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum